Although continued advances have been made in the treatment of acute myeloid leukemia (AML), approximately 20-30% of patients will never achieve a remission. For these patients with primary refractory AML, the only curative option remains an allogeneic stem cell transplant. Allogeneic transplantation provides the ability to administer myeloablative doses of chemotherapy or chemoradiotherapy, as well as the advantage of a possible graftversus-leukemia effect. Difficulty in interpreting the literature is due to selection bias, in particular, the varying definitions of primary refractory disease with respect to the morphological criteria and the number of induction regimen required before being defined as being refractory. Regardless, it is a procedure with high treatment-related mortality and risk of relapse. Most studies demonstrate an event-free survival of 10-20% at 5 years. Predictive factors of outcome include blast cell count in the marrow, karyotype, the number of prior regimen, age, performance status and availability of a related donor. These prognostic factors should be considered prior to offering allogeneic transplantation for primary refractory AML. Those patients with many favorable prognostic factors and an HLAmatched related donor available would be the best candidate for the procedure. Those with many poor prognostic factors and only an unrelated donor available may be better served by being offered palliation or being enrolled in investigational studies.
ation; primary refractory AML Initial use of allogeneic stem cell transplant (allo-SCT) for malignant diseases reported from Seattle was in the setting of advanced acute leukemia including relapsed and refractory acute myeloid leukemia (AML). 1 Although the majority of patients died, a small number survived without disease giving hope that an allo-SCT would be able to cure a significant number of patients. Over the past 30 years, hematopoietic stem cell transplantation has proven to be a successful treatment modality for patients with many different malignant and non malignant diseases resulting in cure. Regardless, AML remains the most common indication for alloSCT with more than 10 000 patients with AML receiving allo-SCT reported to the International Bone Marrow Transplant Registry (IBMTR) between 1998 and 2003. Currently, the majority of patients with AML proceed to allo-SCT in their first or subsequent remission. However, what has happened to the outcome of patients who have never achieved a remission? This paper will review the available published literature on the use of allo-SCT as definitive treatment for patients with AML who never achieve a remission, who will henceforth be termed patients with primary refractory AML and the evidence supporting this treatment modality. Data on patients who previously attained remission will not be included in order to present a clear and focused analysis.
Treatment of AML
In the past 30 years, since the initial report from Seattle, significant advances have been made in the treatment and the understanding of the biology of AML. There has been a proliferation of research in the cytogenetic changes associated with leukemia. For AML, this has led to prognostication based on karyotype and application of novel directed therapy. 2, 3 For acute promyelocytic leukemia (APL) in particular, treatment has become more rational with the use of all-trans retinoic acid (ATRA) and arsenic trioxide leading to extremely high cure and salvage rates. [4] [5] [6] For AML, other than APL, the initial treatment now incorporates the use of high-dose cytosine arabinoside (HDAC), resulting in improved leukemia-free survival. 7 In spite of the advances in conventional treatment of AML, there remain 20-30% of patients who will not achieve a remission with induction chemotherapy. Those at highest risk of induction failure include patients with poor risk karyotype, therapy-induced AML and secondary AML. 2, 3, 8 For this group of patients, the prognosis is poor with limited options. In general, patients with primary refractory AML are offered experimental therapies or palliation. A number of these patients will have a suitably matched related or unrelated donor available for consideration of an allo-SCT. What is the role of allo-SCT for these patients? Are the results any better or worse than when this treatment was first described?
Allo-SCT for AML
The benefit of an allo-SCT as a treatment modality include high doses of chemoradiotherapy to eradicate the leukemia; the replacement of the diseased bone marrow with a bone marrow free of leukemia from a healthy donor and the benefit of the graft-versus-leukemia (GVL) effect. 9 The greatest benefit of GVL is when the malignancy is at an indolent stage such that time can be afforded for the GVL effect to occur such as in the chronic phase of chronic myeloid leukemia. 10 GVL is also clearly present in AML but with less impressive results. In an effort to produce durable remissions, allo-SCT is offered most frequently to patients with AML at high risk of relapse in their first or subsequent remission, appreciating the advantage that may be gained from this procedure at a state of minimal residual disease. Although evidence supports its benefit compared to chemotherapy and possible autologous SCT, these benefits are attenuated by the increased treatment-related mortality. 11, 12 Deciding if and when allo-SCT is appropriate can be difficult, since the increased risk of treatment-related mortality dampens the enthusiasm of its use when a durable remission is possible with chemotherapy. For a patient with refractory AML, the decision process is simpler as by definition, chemotherapy has failed and an autologous SCT is not possible because of the inability to clear the bone marrow of leukemia. The only medical decision for the patient with refractory AML is whether to proceed with noncurative therapies or to pursue an allo-SCT in the hopes of a cure.
Owing to the advanced state of disease, the increased risk of relapse and the high treatment-related mortality, the survival following allo-SCT will be significantly less than for those with less advanced disease. Difficult to quantify is the tremendous social, emotional and financial impact of an allo-SCT, which may offer a marginal hope of a cure and a high chance of failure. However, for a person facing certain death, the potential benefit, however remote, may be well worth the risk and cost, as the allo-SCT remains the only curative option in this circumstance. For these reasons, attempts to determine which factors predict for a better outcome is of paramount importance.
Selection bias
Although patients with primary refractory AML are not uncommon, the published experience of the use of allo-SCT for patients in this situation is relatively small and all studies are retrospective. This partially results from the extensive selection bias that occurs before offering allo-SCT for any purpose (Table 1 ). In spite of advances in the field of transplantation, this treatment is still limited to patients who are fit enough to tolerate it. Many transplant centers will use age as an absolute or relative contraindication to its use. Poor performance status, inadequate organ function and the presence of an active infection also serve contraindications to its use. This becomes more of an issue if repeated attempts at remission induction are made prior to considering an allograft. In addition, transplantation for uncontrolled leukemia is not offered at all centers.
What is published is retrospective, with cases collected over a prolonged period and with variable follow-up. The patient populations are not well characterized with lack of pertinent information such as karyotype. Specifically, two important selection biases specific to the situation are found in publications that report on experiences treating patients with primary refractory AML, proceeding to allo-SCT. The first is the hematopathology definition of refractory leukemia used by the investigators. The second factor is the initial therapy the patient received before being determined to have refractory disease. Unfortunately, the reported studies either have varying definitions and Table 1 Limitations of allogeneic stem cell transplantation for primary refractory AML
Limitation Comment
Eligibility for SCT Transplant centers typically have criteria that patients must meet before allo-SCT can be offered. These criteria will include patient's physical status as well as the availability of an 'appropriate' donor. This results in a significant reduction of patients who are eligible for allo-SCT with only the fittest patients being offered the procedure. therapies in determining that the patient has refractory leukemia or give minimal descriptions of pertinent patient characteristics. This is understandable given that patients reported in these series were typically treated over many years and exposed to a variety of different treatment regimens.
What is primary refractory AML?
The NCI sponsored a group of investigators to develop a set of recommendations for disease assessment in 1988. 13 More recently, these recommendations were updated to incorporate more modern techniques of evaluation such as cytogenetic and molecular studies. 14 The updated criteria recognize the subtleties of defining a morphologic complete remission (CR) such as the presence of circulating blasts, and the requirement of response duration. With the evolving definition of CR, it is understandable that most retrospective studies would have varying definitions of refractory disease. Although most studies define CR as having less than 5% blast cells in the bone marrow, other studies also include normalization of peripheral blood counts without circulating blasts and still other studies do not define remission. The inconsistent definitions may lead to classifying patients with 90% blasts in the bone marrow as having refractory disease in the same way that the patients with less than 5% blasts but without normalization of the peripheral blood counts, or with a few blasts in the peripheral blood are classified as having refractory disease. Furthermore, the time to assess remission status after an induction attempt is not well defined and the remission status may change after a wait of just a week or so.
Most studies have minimal data on prior therapy and may include patients who have failed just one prior therapy. Whether patients are required to have failed more than one cycle of induction chemotherapy before being considered as having primary refractory AML is debatable, but it is generally accepted that patients who have failed one cycle will do better than those who have failed more than one cycle. The United Kingdom Medical Research Council (MRC) AML trials have demonstrated that patient with 5-15% blasts after induction using conventional doses of cytosine arabinoside and an anthracycline-based induction chemotherapy have an 89% chance of achieving a CR with a repeat course of chemotherapy. 15 These patients in a partial remission (PR) 'did a bit worse than those in CR with respect to survival but, if they subsequently achieved CR, there was no difference in relapse rate'. Although most other published studies do not demonstrate such an optimistic outcome for patients who are not in CR after induction chemotherapy, the chance of achieving a remission with a second course of therapy makes it important to have a uniform definition of patients with primary refractory disease. Inclusion of patients who have only received one course of induction in the category of refractory AML may positively skew treatment results.
With increased experience with HDAC, it is becoming well recognized that it has the best chance of salvaging patients refractory to initial induction chemotherapy with, all be it a modest advantage. Regimens containing HDAC are in general considered the most appropriate to induce remission for patients who are not in remission after one cycle of a non-HDAC containing induction chemotherapy regimen. Owing to the previous considerations, a more exclusive definition of a patient with primary refractory leukemia may be more appropriate. A possible definition may be a patient with 15% or greater blast percentage in the marrow after having been treated with two cycles of chemotherapy or with one cycle only if that cycle contained HDAC. Interpreting published data must be performed with these important caveats in mind.
Published results
Publications on this subject are few and all are retrospective studies. [16] [17] [18] [19] [20] [21] [22] [23] [24] These studies are both multicenter and single center with patients accrued over an extended period of time using various initial antileukemia therapy and SCT conditioning regimens. Most of these publications include children as well as adults, patients with acute lymphoblastic leukemia (ALL) and/or patients with relapsed leukemia making interpretation of the data difficult. Regardless, these studies are instructive and give some guidance in understanding the role of allo-SCT for primary refractory AML. Only studies that have reported on 20 or more patients will be discussed in the hope of making general conclusions on outcome and prognostic indicators of outcome ( Table 2) .
The largest single institution series and the best described published in manuscript form is from the City of Hope Comprehensive Cancer Center (CHCCC) updated from their series published a decade prior. 16, 21 Between 1978 and 2000, 68 patients with primary refractory AML proceed to allo-SCT. Some of the more pertinent characteristics are listed in Table 2 . Patients included in their series had bone marrow blast counts between 1 and 490%. Presumably, the patients with blasts o5% had blasts in the peripheral blood or did not have normalization of the peripheral blood counts. Other important features of the included patients were that 40% of them did not receive more than one cycle of induction chemotherapy and 40% did not receive a HDAC containing regimen. In their analysis, they report that the 3-year cumulative probability of disease-free survival was 31% (95% CI 20-42%). Closer examination of the data reveals several relapses between the third and fourth year, making the 4 year disease-free survival closer to 20%. Karyotype analysis was available for 50 of the 68 patients. An important finding in multivariate analysis was that unfavorable karyotype and the use of an unrelated donor predicted for a worse result. An impressive 44% of patients with intermediate risk karyotype remain alive without disease at 3 years compared to 18% for patients with an unfavorable karyotype. Of 12 patients, who had an unrelated donor as the stem cell source, 11 were dead or relapsed within a year of transplant. The number of cycles of prior induction chemotherapy, prior treatment with HDAC-based regimen, percentage of blasts in the blood or bone marrow before SCT and the development of chronic GVHD did not influence outcome.
The Socie´te´Franc¸aise de Greffe de Moelle (SFGM) published a series examining the use of allo-SCT for 379 patients with advanced AML. 20 In their series, 69 patients were transplanted with primary resistant disease. Although characteristics of these patients are not well described, the 5-year probability of survival was 1378%. Analysis for prognostic factors for all 379 patients demonstrated that age greater than 15 years, donor other than a matched sibling and greater than grade 2 acute GVHD predicted for a worse outcome. Although this analysis was not limited to patients with primary refractory leukemia, it helps guide prognostication for this group.
In 1992, the IBMTR published on a series of patients who received HLA-identical sibling bone marrow transplants for acute leukemia who had never achieved a remission with chemotherapy. 17 In all, 88 of the patients had AML. Although patients included in this study were required to have had at least two cycles of chemotherapy, similar to the CHCCC paper this series also has patients with bone marrow blasts less than 5%. In fact, the median bone marrow blasts were 25% (range 0-97%). The 3-year probability of leukemia-free survival was 21% (range 14-31%). In this analysis, a blast count o25% in the bone marrow predicted for a more favorable outcome with 3-year probability of disease-free survival of 32% (18-47%) compared to 12% (1-13%) for those with greater than 25% blasts. Disease-free survival was also superior for patients treated with two or three courses of induction therapy vs four or more courses.
The European Group for Blood and Bone Marrow Transplantation (EBMT) recently reported the results of an analysis examining the outcome of patients with AML not in remission who underwent HLA-identical sibling allo-SCT. 24 The 346 patients with primary refractory disease analyzed proceeded to matched sibling allo-SCT at a median of 136 days after initial diagnosis. No information concerning induction therapy, number of chemotherapies and blast percentage was given. With a median follow-up of 22 months, the leukemia-free survival was 1872% at 2 years. Relapse incidence was 5776% and treatment-related mortality was 2575%.
Grigg et al 19 reported a multicenter Australian study that had 43 patients with refractory AML, but analyzed this group combined with 13 patients with pre-B ALL. Although it is difficult to tease out the exact survival for patients with AML on the graph, it seems to be approximately 20% at 5-years. It is also stated that eight of the 43 patients with AML remain alive at a median of 7 years (range 0.5-14 years). These patients are not specifically described other than to mention that all received 7 days of cytarabine and 3 days of an anthracycline in their initial course of therapy. The number of courses of chemotherapy is not mentioned. Few of these patients received HDAC.
The Royal Marsden group reported on their experience with transplanting 24 patients with primary refractory acute leukemia, of which 20 had AML. 18 All patients were treated with two cycles of induction chemotherapy other than two patients with AML who had greater than 50% blasts in the bone marrow after a single cycle of induction with regimen containing HDAC. Although a CR was achieved in 17 of 20 evaluable patients, the 5-year probability of surviving in remission for all patients is 12%. In fact, one patient relapsed at 48 months and only two patients were alive without disease after 4 years. The report did not indicate if these patients had AML or ALL.
The MD Anderson Cancer Center recently published a paper examining their results of patients who underwent allo-SCT for relapsed or refractory AML or myelodysplastic syndrome (MDS). 23 Interpreting this paper's results for patients with primary induction failure AML is somewhat difficult because of the mix of patients with AML and MDS as well as the inclusion of relapsed patients. In their description of patient characteristics of the 135 patients, 53 patients are considered to have primary induction failure. Although the median number of prior therapy for refractory disease was two, the range was from 0 to 9. How patients receiving zero prior therapies had induction failure or relapse refractory disease was determined is uncertain. Event-free survival at 2 years for the 53 patients is 26%, although several events occur between the second and third year in the Kaplan-Meier curve for all patients, suggesting that with longer follow-up survival is worse. In univariate analysis of all the patients in the study, performance status, X2 prior therapies, disease status beyond first relapse, X10% bone marrow blasts, high peripheral blast count and low albumin were predictive of progression-free survival. In multivariate analysis, performance status, peripheral blood blasts and tacrolimus exposure within the first 11 days were predictive of survival. The influence of karyotype was not mentioned.
Causes of treatment failure
Understandably, given the small number of patients in the majority of the published studies and the different selection criteria, the results are somewhat variable, but important information can be obtained to help predict the response of a patient with primary refractory AML who undergoes an allo-SCT. Although some of the studies report high CR rates, consistently greater than 50% of patients are reported to have persistent disease or relapse post allo-SCT. These relapses occur quickly and mostly within the first year of allo-SCT, due to the resistance and proliferative capacity of these leukemia cells. This clearly demonstrates that although the attainment of remission with the conditioning regimen is possible and likely necessary, it in no way guarantees that the leukemia will be fully eradicated or that the GVL effect can be predictably counted on for a long-term leukemia-free survival. The other major cause of treatment failure is the toxicity which is reported to be anywhere from similar to patients allografted in CR1 to greater than 50%. The selection bias and the increased comorbidities would predict the variable but increased nonrelapse mortality. The use of reduced intensity conditioning would potentially reduce treatment-related complications at the risk of increased relapse. The only study with a significant number of patients receiving reduced-intensity conditioning is in the MD Anderson study, which did not mention conditioning as a prognostic variable. In fact, none of the studies demonstrated an effect of the different myeloablative regimens on outcome. Owing to the high risk of failure in this patient population, prognostication is extremely helpful in deciding which patients should be offered the procedure. Most of the reported patients had an HLAmatched sibling as the source of the allograft. In the CHCCC study, the few patients with an unrelated donor did statistically worse than those with related donors. The exact cause of the inferior outcome is not described, although broad conclusions would be difficult to make because of the small number of patients. The CHCCC study was also the only study to analyze the effect of karyotype at diagnosis. Not unexpectedly, patient with intermediate risk karyotype did significantly better than those with poor risk karyotype. Interestingly, the blast percentage was not found to be significant in the CHCCC study, although the IBMTR study found that having o25% blasts predicted for a better outcome. Other factors examined that did not consistently have predictive value were the number of induction cycles, age at transplant and the occurrence of graft-versus-host disease. Based on these results pretransplant prognostic factors can be derived to help determine the appropriateness and to guide the decision to proceed to allo-SCT (Table 3) .
Future directions
With research efforts to cure AML being focused on initial treatment, over time it is likely that a lower percentage of patients will suffer from primary refractory AML. These patients will have leukemia even more resistant than the previously reported patients. Current approaches of allo-SCT for these patients will at best be as good as and possibly worse than the reported results. If improvements are to be made, creative approaches to transplant must be investigated, which will lead to improved results for allo-SCT for AML in general and by extension allo-SCT for primary refractory AML in particular ( Table 4 ). The major areas of development remain improvements in donor selection and stem cell source, transplant conditioning therapy, supportive care and post transplant prevention of relapse.
Over the past 10 years, molecular tissue typing has increased in use. These improved methods will lead to selection of better matched unrelated donors resulting in lower treatment-related mortality, which will increase overall and event-free survival. 25 Recent data have also demonstrated that donor killer immunoglobulin-like receptors (KIR) and recipient ligand compatibility influence the risk of relapse of myeloid malignancies with incompatible combinations doing better. 26, 27 For patients who have more than one possible donor, choosing the donor who is KIR ligand incompatible may be of importance. The use of peripheral blood stem cells and a high CD34 cell dose may also have a positive effect by reducing the period of neutropenia and increasing the incidence of chronic GVHD thereby reducing relapse. 28, 29 Increasing the intensity of conditioning regimens will likely only increase toxicity and not increase survival. Thus, attempts at maximal leukemia control will probably be less Table 3 Potential favorable prognostic factors to help decide to proceed to allo-SCT Modifications of conditioning therapy to target the malignancy more directly and intensely without increasing toxicity to other organs in the setting of autologous SCT are currently being used for hematological malignancies such as myeloma and lymphoma. [32] [33] [34] For leukemia, several different radiolabeled antibodies have been assessed such as 131 I-anti-CD45 antibody, which may possibly be used as a part of transplant conditioning. 34, 35 Although problems with toxicity have been encountered, modifications may lead to clinical use in combination with traditional chemotherapy leading to increased antitumor effect. 36 In addition to radiolabeled antibodies, antibodies labeled with toxins such as the diphtheria toxinlabeled antibody directed against the GMCSF receptor may allow additional mechanisms of tumor eradication, which may compliment the used of more traditional chemotherapies. 37 Toxicities of these approaches will have to be addressed.
Advances in supportive care will hopefully lead to reductions in infectious complications as well as reduced GVHD. Newer methods of fungus infection detection and newer antifungal medications such as caspofungin, micafungin and voriconazole have led to better prophylaxis and control of infectious complications. 38 Exciting research with keratinocyte growth factor (KGF) has recently demonstrated reduced mucosal toxicity for those undergoing auto-SCT with radiation as part of the conditioning regimen. 39 Preclinical data also suggests that the use of KGF may result in less severe GVHD without reducing the GVL effect by maintaining mucosal integrity, leading to the reduction of serum lipopolysaccharide (LPS) and tumor necrosis factor (TNF), which are important in generating acute GVHD. 40 Anti-inflammatory molecules such as suberoylanilide hydroxamic acid (SAHA) are also being investigated in the hopes of a similar effect. 41 Strategies to decrease the risk of relapse post transplant remain of paramount importance. One possible way of reducing relapse would be the use of maintenance therapy with medications developed to target-specific mutations found in AML cells such as FLT-3 mutations. 42 This approach has already been demonstrated to be effective for patients with CML and Philadelphia chromosome-positive ALL who have relapsed post-allo-SCT, and are treated with imatinib. 43, 44 Such patients have achieved remissions as well as evidence of GVHD as the leukemia clones are controlled. Another future possibility is to use vaccine therapy around the time of transplantation. Although vaccination of the donor prior to stem cell donation has been investigated in mouse models, this approach appears to be too toxic. Post-allo-SCT vaccination of the recipients appears to be a more promising approach. 45 The use of donor lymphocytes, which have been selectively depleted to prevent GVHD but retain GVL may be a possible strategy to reduce post transplant relapse. 46 
Conclusions
The only curative option available for patients suffering from primary refractory AML is an allo-SCT. Although the available literature on this topic includes a heterogeneous group of patients with considerable selection bias, consistently the disease-free survival at 5 years is reported at 10-20%. However, for the patient facing certain death without an allo-SCT, this chance of survival may be worth the financial, emotional and physical investment. In order to maximize the possible benefit, consideration should be given to the number of positive prognostic factors (Table 3) in selecting the patients who should be offered an allo-SCT. For those with numerous negative prognostic factors, it may be considered inappropriate to offer a treatment with diminishing returns. Advances in donor selection, transplant conditioning therapy, supportive care and post transplant treatment strategies may lead to improvements. In spite of these promising areas of investigation, hopefully the future will make the patient with primary refractory AML a diminishing population.
